What is Manifold?
Manifold is dedicated to revolutionizing the life sciences sector by providing an AI-driven platform that expedites critical workflows from initial target identification through clinical development, market access, and precision medicine applications. The platform is engineered to maintain the stringent governance standards required in the life sciences industry. Global corporations and leading research institutions leverage Manifold to enhance operational speed and effectiveness, ultimately aiming to bring life-changing therapies to patients faster. The company's solutions are utilized by tens of thousands of users across hundreds of organizations worldwide.
How much funding has Manifold raised?
Manifold has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2024): $15M with participation from TQ Ventures, SK Ventures, and Calibrate Ventures
Key Investors in Manifold
TQ Ventures
TQ Ventures is a venture capital firm based in New York City, focusing on B2B and some B2C models with durable competitive advantages. They provide differentiated support and networks to founders from startups to Series A and beyond, particularly in fintech, healthcare, and blockchain.
SK Ventures
SK Ventures is a seed-stage investment firm that supports science-driven entrepreneurs, offering practical guidance, valuable connections, and pathways to further funding. They focus on technology-driven startups and provide insights from experienced partners.
Calibrate Ventures
Calibrate Ventures invests in early-revenue companies transforming industries with advanced software, automation, and AI. They partner with companies to accelerate growth and commercialization through financing and operational guidance, leveraging their network and expertise.
What's next for Manifold?
With its recent major strategic investment, Manifold is poised for accelerated growth and expanded market penetration. The substantial backing, characterized as enterprise-level funding, suggests a strategic focus on scaling operations, enhancing product development, and potentially forging new partnerships within the life sciences ecosystem. This capital will likely be instrumental in further developing their AI capabilities, broadening their user base, and solidifying their position as a key enabler of innovation in drug discovery and development. The company's trajectory indicates a move towards broader adoption and impact in bringing novel medicines to market.
See full Manifold company page
